Scynexis (SCYX) news
Recent news
Scynexis announces inducement award under Nasdaq listing rule 5635(c)(4)
AInvest Wire · 5d agoScynexis Q2 EPS USD 0.63
In the second quarter of 2023, SCYNEXIS reported net income of $122.3 million, or $2.56 basic income per share and $2.46 diluted income per share, compared to a net loss of $13.3 million , or $0.31 basic and diluted loss per share for Q2 2022. The company's financial performance was significantly…
AInvest Wire · Aug 10, 2026Scynexis - may receive up to $146 mln in annual net sales milestones & net royalties in the low to mid-single digit range
SCYNEXIS (NASDAQ: SCYX) is positioned to receive up to $146 million in annual net sales milestones and net royalties in the low to mid-single digit range following the relaunch of BREXAFEMME, its antifungal therapy licensed to GlaxoSmithKline (GSK). This potential revenue stream is contingent on…
AInvest Wire · Aug 10, 2026Scynexis Q2 net income USD 7.397 million
AInvest Wire · Aug 10, 2026Scynexis - topline phase 1 data expected in Q3 2026
AInvest Wire · Jun 30, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.